PIK3CA and head and neck squamous cell carcinoma: Numerous preclinical studies in HNSCC xenografts with PIK3CA mutations demonstrated the susceptibility of these tumors to PI3K/AKT/mTOR inhibitors [62,63,64,65,66,67,68,69], supporting their clinical development.